AMGN [NASD]
Amgen Inc.
IndexDJIA S&P500 P/E24.18 EPS (ttm)10.16 Insider Own0.20% Shs Outstand548.00M Perf Week0.07%
Market Cap129.95B Forward P/E12.94 EPS next Y18.98 Insider Trans-1.31% Shs Float533.13M Perf Month-3.11%
Income5.72B PEG3.40 EPS next Q4.40 Inst Own81.20% Short Float3.81% Perf Quarter1.54%
Sales26.32B P/S4.94 EPS this Y-16.50% Inst Trans-0.23% Short Ratio6.13 Perf Half Y8.42%
Book/sh1.67 P/B147.04 EPS next Y8.81% ROA9.30% Target Price250.03 Perf Year-0.55%
Cash/sh12.36 P/C19.86 EPS next 5Y7.10% ROE95.10% 52W Range198.64 - 258.45 Perf YTD9.15%
Dividend7.76 P/FCF29.94 EPS past 5Y0.10% ROI17.10% 52W High-4.99% Beta0.58
Dividend %3.16% Quick Ratio1.10 Sales past 5Y2.50% Gross Margin75.20% 52W Low23.62% ATR4.71
Employees24200 Current Ratio1.40 Sales Q/Q5.70% Oper. Margin30.40% RSI (14)54.41 Volatility1.60% 1.94%
OptionableYes Debt/Eq40.23 EPS Q/Q-5.40% Profit Margin21.70% Rel Volume0.83 Prev Close243.30
ShortableYes LT Debt/Eq39.31 EarningsApr 27 AMC Payout70.80% Avg Volume3.31M Price245.55
Recom2.60 SMA201.61% SMA500.69% SMA2007.87% Volume2,745,350 Change0.92%
May-23-22Initiated SVB Leerink Mkt Perform $256
Feb-09-22Reiterated Wells Fargo Equal Weight $210 → $250
Feb-09-22Reiterated Oppenheimer Outperform $272 → $285
Feb-09-22Reiterated Morgan Stanley Equal-Weight $235 → $238
Feb-09-22Reiterated Jefferies Buy $266 → $280
Feb-09-22Reiterated Barclays Equal Weight $228 → $233
Jan-05-22Downgrade BofA Securities Buy → Neutral $285 → $255
Dec-09-21Resumed Wells Fargo Equal Weight $210
Dec-06-21Initiated Goldman Buy $258
Nov-19-21Initiated BMO Capital Markets Market Perform $228
Sep-23-21Downgrade Daiwa Securities Outperform → Neutral $220
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $280 → $251
Dec-29-20Initiated Daiwa Securities Buy $300
Oct-28-20Initiated UBS Neutral $232
Oct-26-20Upgrade Raymond James Mkt Perform → Outperform $255
Oct-12-20Upgrade Truist Hold → Buy
Oct-09-20Downgrade Truist Buy → Hold $251
Oct-09-20Downgrade Bernstein Outperform → Mkt Perform
Oct-08-20Downgrade Raymond James Outperform → Mkt Perform
Apr-15-20Resumed Guggenheim Neutral
Jul-01-22 10:00AM  
07:26AM  
Jun-30-22 05:37PM  
Jun-28-22 05:50PM  
Jun-27-22 06:00PM  
07:30AM  
Jun-22-22 10:32AM  
Jun-20-22 05:50PM  
09:00AM  
Jun-15-22 09:47AM  
08:23AM  
Jun-14-22 06:00PM  
01:13PM  
Jun-11-22 10:53AM  
06:43AM  
Jun-10-22 04:00PM  
08:00AM  
Jun-09-22 06:00AM  
Jun-08-22 05:50PM  
11:45AM  
Jun-07-22 07:21PM  
04:04PM  
Jun-06-22 06:21PM  
09:00AM  
Jun-05-22 08:00AM  
08:00AM  
Jun-03-22 04:00PM  
11:31AM  
Jun-02-22 11:31AM  
Jun-01-22 08:47AM  
May-31-22 09:00AM  
May-27-22 04:11PM  
02:39PM  
12:11PM  
10:00AM  
May-26-22 05:00PM  
05:00PM  
07:51AM  
04:27AM  
May-25-22 09:11AM  
May-23-22 11:46AM  
10:30AM  
May-20-22 02:17PM  
12:54PM  
May-19-22 07:43AM  
May-17-22 06:15AM  
May-13-22 02:29PM  
08:33AM  
May-12-22 12:45PM  
08:00AM  
06:12AM  
May-10-22 02:05PM  
May-06-22 04:00PM  
12:43PM  
07:33AM  
May-05-22 11:00PM  
03:33PM  
08:20AM  
May-04-22 01:39PM  
May-03-22 03:01PM  
10:42AM  
06:20AM  
06:01AM  
May-02-22 09:00AM  
May-01-22 06:45AM  
Apr-29-22 11:20AM  
Apr-28-22 04:21PM  
01:44PM  
01:33PM  
10:44AM  
09:33AM  
06:30AM  
04:51AM  
02:07AM  
Apr-27-22 05:28PM  
05:25PM  
05:03PM  
04:52PM  
04:34PM  
04:34PM  
04:26PM  
04:01PM  
09:00AM  
08:02AM  
06:01AM  
Apr-26-22 11:44AM  
11:15AM  
05:50AM  
Apr-25-22 11:49AM  
08:44AM  
06:18AM  
Apr-22-22 04:00PM  
09:53AM  
07:50AM  
Apr-21-22 06:00PM  
Apr-20-22 12:10PM  
08:23AM  
Apr-19-22 06:15PM  
03:00PM  
10:57AM  
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williams R SandersDirectorMay 23Sale250.00600150,0005,501May 23 09:19 PM
Graham Jonathan PEVP, Gen. Counsel & Secy.May 10Sale241.8113,5003,264,45437,333May 10 07:45 PM